<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688207</url>
  </required_header>
  <id_info>
    <org_study_id>AVA109941</org_study_id>
    <nct_id>NCT00688207</nct_id>
  </id_info>
  <brief_title>Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)</brief_title>
  <official_title>An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as&#xD;
      monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be&#xD;
      obtained from the current phase III trials . The study aims to enroll fourteen patients&#xD;
      (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR&#xD;
      in the morning under fasted conditions and PK samples will be taken up to 36h.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-inf) and Cmax of RSG XR</measure>
    <time_frame>Up to 36 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t), t1/2 and tmax for RSG XR</measure>
    <time_frame>Up to 36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone (Extended Release)</intervention_name>
    <description>open-label, single, oral, 4mg dose</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects with a clinical diagnosis of probable Alzheimer's disease in&#xD;
&#xD;
          -  accordance with NINCDS-ADRDA3 criteria for at least 3 months&#xD;
&#xD;
          -  Subject has mild Alzheimer's disease as defined by a MMSE score 18 to 26 inclusive&#xD;
&#xD;
          -  at Screening&#xD;
&#xD;
          -  Hachinski Ischemia Score ≤ 4 at Screening&#xD;
&#xD;
          -  Subjects aged ≥50 and ≤90 years.&#xD;
&#xD;
          -  Subject has not taken an approved Alzheimer's therapy in the last 30 days.&#xD;
&#xD;
          -  Current use of medication is in accordance with the criteria listed in Section 9.1).&#xD;
&#xD;
          -  Female subjects must be post-menopausal (i.e. &gt;1 year without menstrual period),&#xD;
&#xD;
          -  surgically sterile, or agree to use adequate method of contraception for the duration&#xD;
             of the study.&#xD;
&#xD;
          -  Female subjects who are pre-menopausal or who have been postmenopausal for &lt;1 year&#xD;
             must undertake pregnancy testing at screening, which must&#xD;
&#xD;
          -  be negative. More than one pregnancy test may be required (i.e., when the time period&#xD;
             between enrolment and study treatment is &gt; 7 days).&#xD;
&#xD;
          -  Pregnancy testing will be performed at screening, pre-dose (Day 1) and follow-up visit&#xD;
             for all women of child-bearing potential and those who have been postmenopausal for&#xD;
             less than 1 year. If clinically indicated, a urine or serum pregnancy test may be&#xD;
             performed at anytime during the study.&#xD;
&#xD;
          -  Brain CT or MRI scan performed within the past 12 months or at Screening, showing no&#xD;
             evidence of any other potential cause of dementia other than Alzheimer's disease.&#xD;
&#xD;
          -  Neurological exam without focal changes (excluding changes attributable to AD or&#xD;
             peripheral trauma).&#xD;
&#xD;
          -  Subjects who live with or who have a regular caregiver who is willing to attend all&#xD;
             visits, oversee the subject's compliance with the protocol specified procedures and&#xD;
             study medication, and who is willing to report on subject's status.&#xD;
&#xD;
          -  Subject has provided full written informed consent prior to the performance of any&#xD;
             protocol-specified procedure.&#xD;
&#xD;
          -  Subjects considered for enrolment must have a QTc (either QTc B (Bazett's&#xD;
&#xD;
          -  correction) or QTc F (Fridericia's correction)) &lt;450msec at the Screening Visit, with&#xD;
             the exception of subjects with bundle branch block (for whom either QTc B or QTc F&#xD;
             must be &lt;480msec).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of possible, probable, or definite vascular dementia in accordance with&#xD;
             NINDS-AIREN6 criteria&#xD;
&#xD;
          -  History or evidence of any other CNS disorder that could be interpreted as a cause of&#xD;
             dementia: e.g. cerebrovascular disease (stroke, hemorrhage), structural abnormality,&#xD;
             epilepsy, infectious or inflammatory/demyelinating CNS conditions, Parkinson's&#xD;
             disease.&#xD;
&#xD;
          -  Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis&#xD;
             serology or active thyroid dysfunction (particularly that suggestive of&#xD;
             hypothyroidism), including abnormally high or low serum levels of thyroid stimulating&#xD;
             hormone (TSH) that is clinically significant in the opinion of the investigator.&#xD;
&#xD;
          -  History of Type 1 diabetes mellitus or secondary diabetes mellitus.&#xD;
&#xD;
          -  Type 2 diabetes mellitus where the subject is being treated with insulin, a PPARγ&#xD;
             agonist, or an insulin secretagogue (e.g. a sulfonylurea or glitinide).&#xD;
&#xD;
          -  Any patient with an HbA1c ≥8.5%&#xD;
&#xD;
          -  History or clinical/laboratory evidence congestive heart failure defined by the New&#xD;
             York Heart Association criteria (Class I to IV cardiac status) (Appendix 4).&#xD;
&#xD;
          -  History of cardiovascular event within the last 6 months (i.e. intervention,&#xD;
             percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non&#xD;
             Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina] or&#xD;
             significant arrhythmia; or major intervention (e.g. cardiac surgery or angiography&#xD;
             plus stenting) scheduled).&#xD;
&#xD;
          -  History of significant psychiatric illness such as schizophrenia or bipolar affective&#xD;
             disorder that in the opinion of the Investigator would interfere with participation in&#xD;
             the study, major depressive disorder (according to DSM-IV) in the past year, or&#xD;
             current active depression requiring initiation of treatment.&#xD;
&#xD;
          -  History or presence of gastro-intestinal, hepatic, or renal disease or other condition&#xD;
             known to interfere with the absorption, distribution, metabolism, or excretion of&#xD;
             drugs, or any other clinically relevant abnormality, which, in the opinion of the&#xD;
             Investigator, makes the subject unsuitable for inclusion in the study.&#xD;
&#xD;
          -  Clinically significant peripheral oedema at the time of screening.&#xD;
&#xD;
          -  Current or recent drug or alcohol abuse or dependence (defined by DSM-IV criteria for&#xD;
             substance-related disorders), or recent or remote history of the same if that could be&#xD;
             a contributing factor to the dementia.&#xD;
&#xD;
          -  Systolic blood pressure &gt;165 or &lt;90 mmHg or diastolic blood pressure &gt;95 or &lt;60 mmHg&#xD;
             at the time of screening.&#xD;
&#xD;
          -  Clinically significant anaemia (i.e. haemoglobin &lt;11 g/dL for males or &lt;10 g/dL for&#xD;
             females)&#xD;
&#xD;
          -  Patients with GFR ≤50ml/min (assessed by Cockcroft-Gault method ) .&#xD;
&#xD;
          -  ALT, AST, or alkaline phosphatase values &gt;2.5 times the upper limit of normal, total&#xD;
             bilirubin values &gt;1.5 times the upper limit of normal, or history of severe&#xD;
             hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis, Child-Pugh Class B/C).&#xD;
&#xD;
          -  History of a bone marrow transplant.&#xD;
&#xD;
          -  Positive hepatitis B virus, hepatitis C virus or HIV test at screening.&#xD;
&#xD;
          -  Subject is unable (with assistance, if appropriate) to take study medication or is at&#xD;
             risk of non-compliance with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPAR agonist,</keyword>
  <keyword>Rosiglitazone XR,</keyword>
  <keyword>BRL-049653.</keyword>
  <keyword>Alzheimer's disease,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AVA109941</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

